T1	HMM 152 198	safety, efficacy and imaging pharmacodynamics.
T2	HMM 738 742	arm.
T3	HMM 743 782	Exploratory pharmacodynamic assessments
T4	HMM 861 899	A, plasma AUC and C (max) of cediranib
T5	HMM 1032 1065	reduces cediranib plasma exposure
T6	HMM 1199 1234	with sustained antivascular effects
T7	HMM 1269 1308	reductions in DCE-MRI parameters and CT
T8	HMM 1416 1447	Evidence of antitumour activity
T9	HMM 1489 1529	effects upon imaging vascular parameters
